Context
A top-3 global pain brand was losing share to local generics across the GCC despite higher clinical efficacy. The product was clinically superior — but the commercial system around it was fragmented across four markets, each with different distributors, regulatory pathways, and HCP engagement norms.
The Challenge
Senior leadership had two competing diagnoses. Marketing said the issue was awareness. Sales said the issue was pricing. Neither was right. The actual problem was that HCPs in the region weren't differentiating between the brand and generic alternatives at the moment of prescription — and the brand wasn't engineered to be remembered at that moment.
Approach
Three interventions, sequenced over 18 months. First, a market-preference diagnostic across 200+ HCPs and 50+ pharmacists to identify the actual decision triggers. Second, a regional brand framework that translated clinical superiority into emotional preference signals — the brand became associated with a specific patient archetype, not just a molecule. Third, a unified KAM playbook that gave 80+ commercial staff a single way to engage HCPs across the four markets.
Outcome
Category share grew from 19% to 26% across the four markets within 18 months. Prescription velocity in tier-1 HCP segments doubled. The framework continues to drive commercial decisions three years later — the test of whether a system was actually built, or just a campaign.